Is KPV FDA-approved?
No. KPV has not been approved as a drug by the FDA. Approval requires full clinical trials and a New Drug Application; KPV has neither. Being removed from Category 2 in April 2026 changed its compounding status, not its approval status.
Approved vs compoundable vs “research-use” — the distinction that matters
An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. As of April 2026 KPV was removed from Category 2 because the original nominations were withdrawn — but it was not moved to Category 1, so compounding is still not authorized and it is not covered by FDA enforcement discretion. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.
What “not FDA-approved” means here
Most KPV evidence comes from laboratory and animal models of inflammation. Human clinical-trial data establishing benefit and safety for any indication is limited. It was among the substances the FDA treated as raising safety concerns under its 2023 Category 2 action.
Will KPV become legal in 2026?+
Is “research-grade” KPV the same as a medicine?+
Primary sources: FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. KPV is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.